See more : Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (600721.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Frequency Therapeutics, Inc. (FREQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Frequency Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CellSeed Inc. (7776.T) Income Statement Analysis – Financial Results
- Probiotec Limited (PBP.AX) Income Statement Analysis – Financial Results
- Nektar Therapeutics (NKTR) Income Statement Analysis – Financial Results
- Quad M Solutions, Inc. (MMMM) Income Statement Analysis – Financial Results
- GenMont Biotech Incorporation (3164.TW) Income Statement Analysis – Financial Results
Frequency Therapeutics, Inc. (FREQ)
About Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 49.42M | 60.92M | 37.42M | 18.78M | 11.88M | 11.97M |
| General & Administrative | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Other Expenses | 1.06M | -266.00K | 0.00 | 16.00M | 0.00 | 0.00 |
| Operating Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Cost & Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 1.33M | 397.00K | 994.00K | 1.78M | 0.00 | -174.00K |
| Interest Expense | 961.00K | 764.00K | 0.00 | 1.78M | 106.00K | 174.00K |
| Depreciation & Amortization | 2.38M | 2.91M | -80.00K | -145.00K | 654.00K | 531.00K |
| EBITDA | -80.62M | -81.13M | -27.55M | -20.68M | -18.29M | -12.02M |
| EBITDA Ratio | 0.00% | -576.66% | -74.71% | -71.92% | 0.00% | 0.00% |
| Operating Income | -83.00M | -84.03M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | -597.32% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | -640.00K | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.58M | -84.67M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | -601.87% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | -2.00K | 15.00K | 35.00K | -2.74M | -118.00K | 3.93M |
| Net Income | -81.58M | -84.69M | -26.51M | -16.00M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | -601.98% | -71.68% | -55.29% | 0.00% | 0.00% |
| EPS | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| EPS Diluted | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| Weighted Avg Shares Out | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
| Weighted Avg Shares Out (Dil) | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
Frequency Therapeutics to Present at Upcoming Investor Conferences
Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm
Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ
FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
Source: https://incomestatements.info
Category: Stock Reports